CN106265499A - A kind of compound potassium dihydrogn phosphate pharmaceutical composition - Google Patents
A kind of compound potassium dihydrogn phosphate pharmaceutical composition Download PDFInfo
- Publication number
- CN106265499A CN106265499A CN201610831541.8A CN201610831541A CN106265499A CN 106265499 A CN106265499 A CN 106265499A CN 201610831541 A CN201610831541 A CN 201610831541A CN 106265499 A CN106265499 A CN 106265499A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- preparation
- water
- potassium dihydrogen
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 title description 8
- 239000011591 potassium Substances 0.000 title description 8
- 229910052700 potassium Inorganic materials 0.000 title description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title description 7
- 239000010452 phosphate Substances 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 title description 6
- GNSKLFRGEWLPPA-UHFFFAOYSA-M Monopotassium phosphate Chemical class [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims abstract description 27
- 235000019796 monopotassium phosphate Nutrition 0.000 claims abstract description 21
- ZPWVASYFFYYZEW-UHFFFAOYSA-L Dipotassium phosphate Chemical class [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 11
- 239000001301 oxygen Substances 0.000 claims abstract description 11
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000002671 adjuvant Substances 0.000 claims abstract description 5
- 230000000240 adjuvant Effects 0.000 claims abstract description 5
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 12
- 238000007792 addition Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 230000001954 sterilising Effects 0.000 claims description 7
- 239000003610 charcoal Substances 0.000 claims description 6
- 229940105082 medicinal charcoal Drugs 0.000 claims description 6
- 230000001186 cumulative Effects 0.000 claims description 5
- 238000005262 decarbonization Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052698 phosphorus Inorganic materials 0.000 claims description 5
- 239000011574 phosphorus Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 description 11
- 235000021317 phosphate Nutrition 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000005712 crystallization Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- XQGPKZUNMMFTAL-UHFFFAOYSA-L dipotassium;hydrogen phosphate;trihydrate Chemical compound O.O.O.[K+].[K+].OP([O-])([O-])=O XQGPKZUNMMFTAL-UHFFFAOYSA-L 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- SEGLCEQVOFDUPX-UHFFFAOYSA-N Di-(2-ethylhexyl)phosphoric acid Chemical compound CCCCC(CC)COP(O)(=O)OCC(CC)CCCC SEGLCEQVOFDUPX-UHFFFAOYSA-N 0.000 description 1
- 206010020583 Hypercalcaemia Diseases 0.000 description 1
- 206010021058 Hypophosphataemia Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 229940046008 Vitamin D Drugs 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- -1 calcium sodium Chemical compound 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004031 devitrification Methods 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000020828 fasting Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000009673 liver disease Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 200000000019 wound Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Abstract
A kind of pharmaceutical composition, is made up of 217 218g potassium dihydrogen phosphates, 319 320g dipotassium hydrogen phosphates and the water as adjuvant as active component in every 1000ml, it is characterized in that the oxygen content in compositions is at below 2mg/L.
Description
Technical field:
The present invention relates to a kind of be made up of potassium dihydrogen phosphate, dipotassium hydrogen phosphate and the water as adjuvant as active component
Pharmaceutical composition and preparation method thereof.
Background technology:
The injectable pharmaceutical compositions being made up of potassium dihydrogen phosphate, dipotassium hydrogen phosphate, is mainly used in total parenteral nutrition and treats
As the supplement of phosphorus in method, as medium above operation or other wounds need the phosphorus supplement of more than 5 days patients of fasting, as various
The multiple chronic disease patients such as operation and wounded patient, cardiovascular and cerebrovascular vessel, hepatopathy；Also can be used for some disease institute to hypophosphatemia.
Kong Xiangwen (disodium hydrogen phosphate and the mensuration respectively of potassium dihydrogen phosphate, Nanjing Medical College in mixed phosphate saline injection
19 88 years the 2nd phases of volume 8 of journal, 173-174 page) report that rod closes phosphate injection and has another name called sodium phosphate injection, it is loaded in " first
All hospital preparation compilation " and " preparation handbook " in, its prescription is disodium hydrogen phosphate (being equivalent to anhydrous product 5.75 9) and di(2-ethylhexyl)phosphate
Hydrogen potassium (anhydrous product 1.309), adds jetting and makes to 100.0ml.This product supplements phosphorus and treatment calcium, potassium, phosphorus generation for intravenous nutrition
Thank disorder, the hypercalcemia that Vitamin D excess causes.
The invention of Application No. CN201010208559.5 relates to the production method of a kind of compound potassium dihydrogn phosphate, depends on
Secondary including dispensing, decolouring, embedding, sterilizing, leak detection, lamp inspection, scald bottle, lettering and packaging step, described production method also includes
After described embedding step, before described packaging step, described injection is carried out heating-cooling at least one times and processes,
Described heating-cooling processes and refers to first be warming up to by injection 40 DEG C～100 DEG C, then gives free rein to be cooled to environment temperature
Degree.Even if gained injection of the present invention runs into the environment of quenching or there will not be crystallization under low temperature storage environment, it is ensured that
The quality of product and serviceability.But this patent only solves devitrification problem from technique, the most fundamentally solve to ask
Topic.
The disclosure of the invention of the Application No. 201210331492.3 Compornd Potassium Dihydrogen phos-phate drug regimen of a kind of injection
Thing, this compound potassium dihydrogn phosphate is made up of potassium dihydrogen phosphate, dipotassium hydrogen phosphate trihydrate, calcium disodium edetate, and every contains
There are potassium dihydrogen phosphate 435.4-870.8mg, dipotassium hydrogen phosphate trihydrate 487.7-975.4mg in terms of dipotassium hydrogen phosphate, according to ground
Acid calcium sodium 1-2mg, water for injection adds to 2L-4L.Its preparation method is: taking recipe quantity water for injection 70%, temperature is at 70-80
DEG C, add the calcium disodium edetate of recipe quantity, after stirring and dissolving；The potassium dihydrogen phosphate and the dipotassium hydrogen phosphate three that add recipe quantity are hydrated
Thing is in terms of dipotassium hydrogen phosphate, and stirring is to dissolving completely；Record original ph, according to original ph, with 4% sodium hydroxide solution and
10% phosphoric acid solution regulation pH value range is at 5.5-6.5；To adding medicinal charcoal, stirring；Sucking filtration, adds water for injection to full dose,
Mix homogeneously；Fine straining；Fill；Sterilizing；Lamp inspection；Warehouse-in；Obtain compound potassium dihydrogn phosphate.This Compornd Potassium Dihydrogen phos-phate medicine group
Compound photostability is good, will not produce crystallization, clarity, good stability, and this invention, to improving product yield, reduces cost,
Realize industrialization, be preferably applied to clinic, there is more obvious advantage.
The most never find that reducing oxygen content has a certain impact for stability tool.
Summary of the invention:
By long-term test, we have surprisingly found that, by the 217-218g phosphoric acid as active component in every 1000ml
The pharmaceutical composition that potassium dihydrogen, 319-320g dipotassium hydrogen phosphate and the water as adjuvant form, when the oxygen content in compositions exists
During below 2mg/L, photostability is good, runs into the environment of quenching or there will not be crystallization under low temperature storage environment.
A kind of pharmaceutical composition, by as the 217-218g potassium dihydrogen phosphate of active component, 319-320g in every 1000ml
Dipotassium hydrogen phosphate and the water as adjuvant form, and it is characterized in that the oxygen content in compositions is at below 2mg/L.
The preparation method of aforementioned pharmaceutical compositions, is characterized in that the water of compositions cumulative volume more than 60% is put into container
In, after addition potassium dihydrogen phosphate, dipotassium hydrogen phosphate are the most molten, it are cooled to 5-10 DEG C, then heat to 80-90 DEG C, be then cooled to
Room temperature, then weigh in 0.3% medicinal charcoal addition container, stir evenly, decarbonization filtering, mend and add water to full dose, stir, be passed through nitrogen
Rear fill.
Above-mentioned preparation method, it is characterized in that adding water to benefit after full dose again by medicinal liquid through 0.22 μm filter element filtering.
Above-mentioned preparation method, keeps after it is characterized in that fill carrying out sterilizing in 15 minutes under the conditions of 120～125 DEG C.
Above-mentioned preparation method, it is characterised in that make the oxygen content in compositions at below 2mg/L after being passed through nitrogen.
Above-mentioned pharmaceutical composition, it is characterised in that route of administration is to enter internal by injection.
In the present invention, dipotassium hydrogen phosphate, potassium dihydrogen phosphate can be corresponding hydrates, but corresponding hydrate is all with it
In dipotassium hydrogen phosphate, potassium dihydrogen phosphate calculate.
Detailed description of the invention
Embodiment 1
Prescription:
| Composition | Embodiment 1-1 | Embodiment 1-2 | Embodiment 1-3 |
| Potassium dihydrogen phosphate (g) | 2170 | 2177 | 2180 |
| Dipotassium hydrogen phosphate (g) | 3190 | 3195 | 3200 |
| Water for injection adds to (ml) | 10000 | 10000 | 10000 |
| Oxygen content (mg/L) | 1.53 | 1.03 | 1.95 |
Preparation method:
Putting in container by the water of cumulative volume more than 60%, the addition potassium dihydrogen phosphate of recipe quantity, dipotassium hydrogen phosphate are the most molten
After, it is cooled to 5-10 DEG C, then heats to 80-90 DEG C, be then cooled to room temperature, then weigh in 0.3% medicinal charcoal addition container,
Stir evenly, decarbonization filtering, mend and add water to full dose, then by medicinal liquid through 0.22 μm filter element filtering, stir, be passed through nitrogen and make compositions
In oxygen content fill after below the 2mg/L.Keep after fill carrying out sterilizing in 15 minutes under the conditions of 120～125 DEG C.
Comparative examples 1
Prescription:
| Composition | Comparative examples 1-1 | Comparative examples 1-2 | Comparative examples 1-3 |
| Potassium dihydrogen phosphate (g) | 2170 | 2177 | 2180 |
| Dipotassium hydrogen phosphate (g) | 3190 | 3195 | 3200 |
| Water for injection adds to (ml) | 10000 | 10000 | 10000 |
| Oxygen content (mg/L) | 3.71 | 2.19 | 7.52 |
Preparation method:
Putting in container by the water of cumulative volume more than 60%, the addition potassium dihydrogen phosphate of recipe quantity, dipotassium hydrogen phosphate are the most molten
After, it is cooled to 5-10 DEG C, then heats to 80-90 DEG C, be then cooled to room temperature, then weigh in 0.3% medicinal charcoal addition container,
Stir evenly, decarbonization filtering, mend and add water to full dose, then by medicinal liquid through 0.22 μm filter element filtering, stir, comparative examples 1-1 and
1-2 is passed through nitrogen, and comparative examples 1-3 is not passed through nitrogen, fill.Keep entering for 15 minutes after fill under the conditions of 120～125 DEG C
Row sterilizing.
Comparative examples 2
Prescription:
| Composition | Comparative examples 2-1 | Comparative examples 2-2 | Comparative examples 2-3 |
| Potassium dihydrogen phosphate (g) | 2000 | 2100 | 2300 |
| Dipotassium hydrogen phosphate (g) | 3000 | 3300 | 3500 |
| Water for injection adds to (ml) | 10000 | 10000 | 10000 |
| Oxygen content (mg/L) | 1.81 | 1.23 | 1.87 |
Preparation method:
Putting in container by the water of cumulative volume more than 60%, the addition potassium dihydrogen phosphate of recipe quantity, dipotassium hydrogen phosphate are the most molten
After, then weigh in 0.3% medicinal charcoal addition container, stir evenly, decarbonization filtering, mend and add water to full dose, then medicinal liquid is filtered through 0.22 μm
Core filters, and stirs, is passed through nitrogen, fill.Keep after fill carrying out sterilizing in 15 minutes under the conditions of 120～125 DEG C.
Test example 1 stability contrast experiment
Each 20 batches are prepared respectively according to the method for embodiment 1, comparative examples 1,2.It is divided into 1 group at random by every 10 batches, point
Do not carry out high temperature, illumination experiment, visual observations experimental result.
1.1 high temperature experiments:
Being placed 30 days in 60 DEG C of thermostatic drying chambers by sample, observe color sample and transparency, result is as follows.
.2 illumination experiment:
Being placed 30 days in 60 DEG C of thermostatic drying chambers by sample, light irradiates 30d (intensity 3 000lx), observes sample
Color and transparency, result is as follows.
Claims (6)
1. a pharmaceutical composition, by as the 217-218g potassium dihydrogen phosphate of active component, 319-320g phosphorus in every 1000ml
Acid hydrogen dipotassium and the water as adjuvant form, and it is characterized in that the oxygen content in compositions is at below 2mg/L.
2. a preparation method for the pharmaceutical composition described in claim 1, is characterized in that compositions cumulative volume more than 60%
Water put in container, add potassium dihydrogen phosphate, dipotassium hydrogen phosphate the most molten after, be cooled to 5-10 DEG C, then heat to 80-90
DEG C, then it is cooled to room temperature, then weighs in 0.3% medicinal charcoal addition container, stir evenly, decarbonization filtering, mend and add water to full dose, stirring
Uniformly, fill after nitrogen it is passed through.
3. the preparation method described in claim 2, filters medicinal liquid through 0.22 μm after it is characterized in that benefit adds water to full dose again
Core filters.
4. the preparation method described in claim 2, keeps 15 minutes after it is characterized in that fill under the conditions of 120～125 DEG C
Carry out sterilizing.
5. preparation method as claimed in claim 2, it is characterised in that make the oxygen content in compositions at 2mg/L after being passed through nitrogen
Below.
6. the pharmaceutical composition described in a claim 1, it is characterised in that route of administration is to enter internal by injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610831541.8A CN106265499A (en) | 2016-09-18 | 2016-09-18 | A kind of compound potassium dihydrogn phosphate pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610831541.8A CN106265499A (en) | 2016-09-18 | 2016-09-18 | A kind of compound potassium dihydrogn phosphate pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106265499A true CN106265499A (en) | 2017-01-04 |
Family
ID=57711547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610831541.8A Pending CN106265499A (en) | 2016-09-18 | 2016-09-18 | A kind of compound potassium dihydrogn phosphate pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106265499A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108619091A (en) * | 2018-06-12 | 2018-10-09 | 南京正科医药股份有限公司 | A kind of compound potassium dihydrogn phosphate |
| WO2020081118A1 (en) * | 2018-10-19 | 2020-04-23 | Cmp Development Llc | Potassium phosphates composition for injection |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010046917A2 (en) * | 2008-10-13 | 2010-04-29 | Intas Pharmaceuticals Limited | Fludarabine phosphate composition |
| CN101926761A (en) * | 2010-06-23 | 2010-12-29 | 苏州天马医药集团天吉生物制药有限公司 | Production method of compound potassium dihydrogn phosphate |
| CN102813675A (en) * | 2012-09-07 | 2012-12-12 | 天津市嵩锐医药科技有限公司 | Compound potassium hydrogen phosphate medicine combination for injection |
-
2016
- 2016-09-18 CN CN201610831541.8A patent/CN106265499A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010046917A2 (en) * | 2008-10-13 | 2010-04-29 | Intas Pharmaceuticals Limited | Fludarabine phosphate composition |
| CN101926761A (en) * | 2010-06-23 | 2010-12-29 | 苏州天马医药集团天吉生物制药有限公司 | Production method of compound potassium dihydrogn phosphate |
| CN102813675A (en) * | 2012-09-07 | 2012-12-12 | 天津市嵩锐医药科技有限公司 | Compound potassium hydrogen phosphate medicine combination for injection |
Non-Patent Citations (2)
| Title |
|---|
| 国家药典委员会: "《中华人民共和国药典 第4部》", 30 June 2015 * |
| 李威，等: "《药剂学》", 28 February 2014, 湖北科学技术出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108619091A (en) * | 2018-06-12 | 2018-10-09 | 南京正科医药股份有限公司 | A kind of compound potassium dihydrogn phosphate |
| CN108619091B (en) * | 2018-06-12 | 2020-10-16 | 南京正科医药股份有限公司 | Compound potassium hydrogen phosphate injection |
| WO2020081118A1 (en) * | 2018-10-19 | 2020-04-23 | Cmp Development Llc | Potassium phosphates composition for injection |
| US10632150B1 (en) | 2018-10-19 | 2020-04-28 | Cmp Development Llc | Potassium phosphates composition for injection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108853011B (en) | Calcium gluconate-L-calcium lactate oral liquid and preparation method thereof | |
| CN102225063B (en) | Pantoprazole sodium composition for injection | |
| CN101455631B (en) | Meglumine cyclic adenosine injection and preparation technique thereof | |
| CN103550143A (en) | Preparation method of levetiracetam injection | |
| CN105434373A (en) | Oxiracetam freeze-drying preparation for injection and preparation method thereof | |
| CN106265499A (en) | A kind of compound potassium dihydrogn phosphate pharmaceutical composition | |
| CN106822175A (en) | A kind of sodium acid carbonate ringer's injection and preparation method thereof | |
| CN103126978A (en) | Preparing method for ambroxol hydrochloride injection | |
| CN102525905A (en) | Tinidazole and sodium chloride injection and preparation method thereof | |
| CN102552186A (en) | Pantoprazole sodium freeze-dried powder injection and preparation method thereof | |
| CN102302502A (en) | Compound glycyrrhizin preparation and preparation method thereof | |
| CN107157925A (en) | Aramine parenteral solution and preparation method thereof | |
| CN103301062A (en) | Medium and long-chain lipid emulsion injection preparation method | |
| CN1399959A (en) | Etomidate fatty emulsion injection preparation method | |
| CN101417105B (en) | Zedoary turmeric oil glucose injection and preparation method thereof | |
| CN104606209A (en) | Compound vitamin medicine composition for injection and preparation method of compound vitamin medicine composition | |
| CN103191431A (en) | Coenzyme Q10 sodium chloride injection uneasy to crystallize and preparation method thereof | |
| CN101244070A (en) | Polyene phosphatidylcholine high-capacity injection | |
| CN103371966A (en) | Lobeline hydrochloride injection and preparation technology thereof | |
| CN108210451B (en) | Stable breviscapine injection and preparation process thereof | |
| CN103432086A (en) | Pemetrexed disodium freeze-dried powder injection for injection and preparation method thereof | |
| CN102772373B (en) | A kind of injection vinorelbine tartrate injectable powder and preparation method thereof | |
| CN103239396B (en) | Sodium ibandronate injection composition and preparation method of sodium ibandronate injection composition | |
| CN102247381A (en) | VitaminD2-and-vitaminE-containing medicinal composition for injection and preparation method thereof | |
| CN106963779A (en) | A kind of production method of compound potassium dihydrogn phosphate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |
|
| RJ01 | Rejection of invention patent application after publication |